Goodwin advised Seagen on the deal. Nurix Therapeutics, Inc. (Nasdaq: NRIX) announced that it has entered into a multi-year, multi-target strategic collaboration agreement with Seagen Inc....
Seagen and Nurix’s Strategic Collaboration
ImmunityBio’s $40 Million Common Stock Offering
Wilson Sonsini advised ImmunityBio, and Goodwin advised the placement agent. ImmunityBio, Inc. (NASDAQ: IBRX) announced that it has executed financing to provide further working capital and support...
Korro Bio and Frequency Therapeutics’ Merger Agreement
Goodwin Procter is serving as legal counsel to Korro Bio, Latham & Watkins is serving as Frequency Therapeutics’ legal counsel, and Davis Polk is serving as...
Akero Therapeutics’s $220 Million Registered Direct Offering
Goodwin advised Akero Therapeutics on the offering, and Cooley advised the underwriter involved. Akero Therapeutics (Nasdaq: AKRO) announced the closing of its underwritten registered direct offering...
TCR² Therapeutics’ Agreement with Adaptimmune Therapeutics
Goodwin advised TCR² Therapeutics Inc. on the deal while Ropes & Gray represented Adaptimmune Therapeutics plc. TCR² Therapeutics Inc. (NASDAQ: TCRR) announced its definitive agreement with Adaptimmune...
ImmunityBio’s $50.0 Million Offering
Goodwin Procter advised Jefferies LLC as exclusive placement agent on the deal. ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, announced that it has executed financing...
Amolyt Pharma’s EUR 138 Million Fund Raising
Goodwin advised Sofinnova Partners, Intermediate Capital Group, Tekla et CTI Life Sciences. Jones Day advised Amolyt Pharma. McDermott Will & Emery advised Andera Partners, Novo Holdings...
Acrivon Therapeutics’ $99.4 Million Initial Public Offering
Goodwin Procter advised the underwriters on the deal. Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines...